Campaigners and medical experts are said to be “alarmed” by the US move to buy up Remdesivir, a medicine proven used to fight coronavirus.
The Trump administration has outbid and out outmanoeuvred all other countries to secure medical supplies for American citizens, leaving next to nothing for the rest of the world, The Guardian reports.
The US Health and Human Services Secretary, Alex Azar, confirmed Trump “struck an amazing deal” to ensure “Americans have access to” coronavirus fighting drugs Remdesivir
The United States has bought up all existing stock of one of two drugs proven to work against Covid-19, which will not be available to any other country on Earth for the next three months.
The US Health and Human Services Secretary, Alex Azar, confirmed Trump “struck an amazing deal” to ensure “Americans have access to the first” treatment.
It is the first drug approved by licensing authorities in the US, and is made by Gilead and has been shown to help people recover from the disease.
“The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”
“To the extent possible, we want to ensure that any American patient who needs Remdesivir can get it.
He said: “President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19.
Dr Andrew Hill, Senior Visiting Research Fellow at Liverpool University said the US has got “access to most of the drug supply” so there’s “nothing left for Europe.”
“Once again we’re at the back of the queue.
“This is the first major approved drug, and where is the mechanism for access?
He told The Guardian: “They’ve got access to most of the drug supply of Remdesivir, so there’s nothing for Europe.
“Imagine this was a vaccine, that would be a firestorm. But perhaps this is a taste of things to come.”
At the time, CEO, Paul Hudson: “The US government has the right to the largest pre-order because it’s invested in taking the risk.
“If we’ve helped you manufacture the doses at risk, we expect to get the doses first.”
The United States tried to corner the coronavirus market in May, when French manufacturer Sanofi said the US would get first access to its Covid vaccine if it works.